Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score 7-10 Prostate Cancer Treated With Permanent Prostate Brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 2, 2009, Pages 341-346

  Stone, Nelson N ^a   Potters, Louis ^b   Davis, Brian J ^c   Ciezki, Jay P ^d   Zelefsky, Michael J ^e   Roach, Mack ^f   Shinohara, Katsuto ^f   Fearn, Paul A ^e   Kattan, Michael W ^d   Stock, Richard G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b North Shore Long Island Jewish Health System ^*  (United States)

^c MAYO CLINIC   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biologic equivalent dose; Brachytherapy; Prostate cancer

Indexed keywords

ANTIGENS; DOSIMETRY; PALLADIUM; REGRESSION ANALYSIS;

BIOCHEMICAL CONTROL RATES; BIOLOGIC EQUIVALENT DOSE; BRACHYTHERAPY; COX REGRESSION ANALYSES; EFFECTIVE DOSES; EXTERNAL BEAM RADIOTHERAPIES; GLEASON SCORES; HORMONAL THERAPIES; MINIMAL DOSES; OVERALL SURVIVAL RATES; POSTIMPLANT DOSIMETRIES; PROSTATE BRACHYTHERAPY; PROSTATE CANCER; TARGET VOLUMES;

QUALITY ASSURANCE;

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMICAL ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RELATIVE BIOLOGICAL EFFECTIVENESS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 58149327450     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.04.038     Document Type: Article

References (29)

1. D'Amico A.V., Moul J., Carroll P.R., et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21 (2003) 2163-2172
2. Kupelian P.A., Katcher J., Levin H.S., et al. Stage T1-2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 37 (1997) 1043-1052
3. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360 (2002) 103-106
4. Stock R.G., Cahlon O., Cesaretti J.A., et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 1352-1359
5. Potters L., Morgenstern C., Calugaru E., et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173 (2005) 1562-1566
6. Critz F.A., and Levinson K. 10-Year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. J Urol 172 (2004) 2232-2238
7. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64 (2006) 527-533
8. Quan A.L., Ciezki J.P., Reddy C.A., et al. Improved biochemical relapse-free survival for patients with large/wide glands treated with prostate seed implantation for localized adenocarcinoma of prostate. Urology 68 (2006) 1237-1241
9. Sengupta S., Davis B.J., Mynderse L.A., et al. Permanent prostate brachytherapy: Pathologic implications as assessed on radical prostatectomy specimens of broadening selection criteria for monotherapy. Urology 68 (2006) 810-814
10. Zelefsky M.J., Yamada Y., Cohen G.N., et al. Intraoperative real-time planned conformal prostate brachytherapy: Post-implantation dosimetric outcome and clinical implications. Radiother Oncol 84 (2007) 185-189
11. Stone N.N., Potters L., Davis B.J., et al. Customized dose prescription for permanent prostate brachytherapy: Insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys 69 (2007) 1472-1477
12. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
13. Kuban D.A., Levy L.B., Potters L., et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 65 (2006) 1487-1493
14. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 296 (2006) 2329-2335
15. Bolla M., van Poppel H., Collette L., et al., European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
16. Amer A.M., Mott J., Mackay R.I., et al. Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 56 (2003) 199-207
17. Cheung R., Tucker S., Dong L., et al. Dose-response for biochemical control among high-risk prostate cancer patients after external beam radiotherapy. Int J Radiat Oncol Biol Phys 56 (2003) 1234-1240
18. Symon Z., Griffith K.A., Mclaughlin W., et al. Dose escalation for localized prostate cancer: Substantial benefit observed with 3D conformal therapy. Int J Radiat Oncol Biol Phys 57 (2003) 384-390
19. Jacob R., Hanlon A.L., Horwitz E.M., et al. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 100 (2003) 538-543
20. Stephenson A.J., and Kattan M.E. Nomograms for prostate cancer. BJU Int 98 (2006) 39-46
21. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
22. Stone N.N., Stock R.G., White I., et al. Patterns of local failure following prostate brachytherapy. J Urol 177 (2007) 1759-1764
23. Tollefson M.K., Leibovich B.C., Slezak J.M., et al. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: Impact on prostate cancer specific survival. J Urol 175 (2006) 547-551
24. Bolla B., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
25. Swanson J.P., Hussey M.A., Tangen C.M., et al. Predominant treatment failure in postprostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25 (2007) 2225-2229
26. Stock R.G., Ho A., Cesaretti J., et al. Changing the patterns of failure for high risk prostate cancer by optimizing local control. Int J Radiat Oncol Biol Phys 66 (2006) 389-394
27. Chen Z., and Nath R. Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives. Int J Radiat Oncol Biol Phys 55 (2003) 825-834
28. Nag S., Beyer D., Freidland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44 (1999) 789-799
29. 90 implant doses of 180 Gy or greater. Int J Radiat Oncol Biol Phys 70 (2008) 96-101